Study summary

A one-time immune-priming dose keeps working years later

HIMALAYA 4-year follow-up · Phase 3 · Published February 2024, Annals of Oncology

What was tested

Durvalumab with a single priming dose of tremelimumab (the "STRIDE" regimen), against sorafenib, as first treatment for unresectable liver cancer, followed about 4 years.

What they found

• Survival benefit over sorafenib held up at 4 years of follow-up.
• No new or late-onset safety problems appeared.

What it means

Supports STRIDE as a durable first-line option, including for some people who cannot have anti-VEGF drugs.